医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Complimentary Ticket to Join YAFO ACCESS CHINA Forum 2021

2020年12月12日 AM01:00
このエントリーをはてなブックマークに追加


 

SHANGHAI

YAFO Life Science and BioToChina.org announced the schedule for ACCESS CHINA Forum 2021 (January 4th - 22nd). As the largest China corporate access event during the JPM Conference weeks, ACCESS CHINA 2021 expects to host more than 30 keynote speakers and 100 company presentations from North America, Europe, China and Rest of Asia. We expect more than 1000 participants from China and the global biopharma industry and investment community. Over 60 global biopharma companies have confirmed presenting. 30 presenters from China include SinoPharm, Fosun, Grand Pharma, Tasly, Shanghai Pharma, Jemincare and 7 MNCs: Abbott, Bayer, MSD, BD, Servier, Merck Serono, and Ipsen.

To facilitate global life science partnering, ACCESS CHINA 2021 participation and company showcase are FREE-OF-CHARGE. The event will also offer 1×1 Meeting System for YAFO clients and investors. For more information and registration, please visit: www.biotochina.org

ACCESS CHINA Forum, organized by YAFO Life Science and BioToChina.org, is the most effective deal-making platform for Western pharma and biotech leaders looking to enter or expand in the Chinese market. ACCESS CHINA creates invaluable BD opportunities by directly connecting and meeting with the right partners for development, licensing or commercial collaborations.

Company roadshows are divided into ten different therapeutic areas:

  • Oncology (3 sessions)
  • Autoimmune Disease
  • CNS, Cardiovascular
  • Cell Therapy, Rare Disease
  • Genitourinary, Gynecology, Pediatric
  • Ophthalmology, Orthopedics
  • Material, Platform Technology
  • Dermatology, Respiratory, Infectious Disease
  • Digestive System, Endocrinology, NASH
  • IVD, Medical Devices

ACCESS CHINA Forum 2021 also has three special sessions:

  • Swiss Innovation Day (Co-organizer: Swiss Biotech Association)
  • Israel Healthcare Showcase
  • MNC Track

About YAFO LIFE SCIENCE

YAFO Life Science (YLS) is the healthcare division of YAFO Capital, which is focused on helping leading U.S. and European Biopharma & MedTech companies to successfully enter the Asian market, especially in China and Japan. YLS also helps domestic pharma companies in global business development and partnering. Along with our local partners, YLS is dedicated to bridging the gap between global medical technologies and the Asian market. www.yafocapital.com

About BioToChina.org

BioToChina.org is the first organization to connect Pharma, Biotech & Medtech BDs in China with the rest of world. With about 500 active members in the pharma industry, BioToChina.org organizes various events (including ACCESS CHINA Forum) throughout the year to facilitate the communications of pharma BDers. www.BioToChina.org

View source version on businesswire.com: https://www.businesswire.com/news/home/20201211005375/en/

CONTACT

Wendi Xiang, Vice President

wxiang@yafocapital.com

+8613733685995

YAFO Capital

同じカテゴリーの記事 

  • Poxel to Report Its 2023 Annual Results by the End of April 2024
  • Kolmar Korea Wins Case Against Italian Cosmetics Maker Intercos for Suncare Technology Theft
  • 大手CDMOのPCIファーマ・サービシズが初の包括ESG報告書を発表
  • Aurion Biotech Announces First Canadian Subject Dosed in Phase 1 / 2 Clinical Trial
  • 领先的合同开发和制造组织PCI Pharma Services发布首份综合ESG报告